DoD Awards Ology Bioservices $135M in Medical Countermeasure Dev’t Contracts

Ology Bioservices has secured a pair of contracts worth $135.4M combined from the Department of Defense to develop a medical countermeasure against biological threats and a technology platform for producing nucleic acids.

The Alachua, Fla.-based biopharmaceutical company said Monday it will explore the use of monoclonal antibodies as a potential treatment for Yersinia pestis, the bacterium that causes plague, under a contract valued at $130.3M over 10 years.

Team members for the project are the Duke Human Vaccine Institute, Battelle, Just Biotherapeutics, Mapp Biopharmaceutical, Cato Research, Certara and the U.S. Army Medical Research Institute of Infectious Diseases.

Under the second contract, valued at $5.1M, Ology Bioservices will create a manufacturing technology prototype to produce plasmid DNA for potential use in genetic vaccines and gene therapy.

The 30-month agreement contains options for the company to facilitate the development of RNA manufacturing platforms.

DoD’s Platforms for Rapid Integrated Solutions for Medical Countermeasures office awarded the two contracts.

You may also be interested in...

Brandon Wales Acting Director CISA

Brandon Wales: CISA’s New Campaign Aims to Help Public, Private Sectors Defend Against Ransomware

The Cybersecurity and Infrastructure Security Agency has launched a campaign to promote the use of cybersecurity tools and best practices to increase ransomware threat awareness across the public and private sectors.

The White House

President Biden Issues COVID-19 Data Collection Order

President Joe Biden has ordered federal agencies to work with the government's COVID-19 response coordinator in efforts to collect, publish and share pandemic-related data and address disinformation or misinformation campaigns regarding the public health crisis.